Back to User profile » Dr Kelly Nichols
Papers published by Dr Kelly Nichols:
Effect of Cyclosporine Ophthalmic Solution 0.09% on Signs and Symptoms of Dry Eye Disease in Patients Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%: Results from a Single-Arm, Open-Label, Phase 4 Study
Johnston J, Adler R, Hessen M, Nichols KK, White D, Saenz B, Bowden F III, Periman LM, Truett K, Urbieta M, Mitchell B
Clinical Ophthalmology 2026, 20:583071
Published Date: 4 March 2026
The Demodex Expert Panel on Treatment and Eyelid Health (DEPTH) Consensus Regarding the Preferred Treatment for Demodex Blepharitis
Donnenfeld E, Nichols KK, Ayres BD, Farid M, Gupta PK, Lindstrom RL, Pflugfelder S, Starr CE, Venkateswaran N, Gaddie IB, Karpecki PM, Koetting C, McGee S, Periman LM, Yeu E
Clinical Ophthalmology 2025, 19:1893-1904
Published Date: 18 June 2025
The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis
Starr CE, Nichols KK, Lang JR, Brady TC
Clinical Ophthalmology 2023, 17:3867-3875
Published Date: 13 December 2023
Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
Farid M, Ayres BD, Donnenfeld E, Gaddie IB, Gupta PK, Holland E, Lindstrom R, Pflugfelder SC, Karpecki PM, Nichols KK, Starr CE, Yeu E
Clinical Ophthalmology 2023, 17:667-679
Published Date: 27 February 2023
Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
Nichols KK, Donnenfeld ED, Lau C, Syntosi A, Karpecki P, Hovanesian JA
Clinical Ophthalmology 2022, 16:909-916
Published Date: 25 March 2022
Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
Hovanesian JA, Nichols KK, Jackson M, Katz J, Chan A, Glassberg MB, Sloesen B, Korves C, Nguyen C, Syntosi A
Clinical Ophthalmology 2021, 15:1041-1054
Published Date: 8 March 2021
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A
Clinical Ophthalmology 2018, 12:913-914
Published Date: 17 May 2018
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A
Clinical Ophthalmology 2018, 12:263-270
Published Date: 31 January 2018
A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day
Blackie CA, Coleman CA, Nichols KK, Jones L, Chen PQ, Melton R, Kading DL, O'Dell LE, Srinivasan S
Clinical Ophthalmology 2018, 12:169-183
Published Date: 17 January 2018
A randomized, double-masked, parallel-group, comparative study to evaluate the clinical efficacy and safety of 1% azithromycin–0.1% dexamethasone combination compared to 1% azithromycin alone, dexamethasone 0.1% alone, and vehicle in the treatment of subjects with blepharitis
Hosseini K, Lindstrom RL, Foulks G, Nichols KK
Clinical Ophthalmology 2016, 10:1495-1503
Published Date: 10 August 2016